|
gptkbp:instanceOf
|
gptkb:drug
gptkb:complement_inhibitor
|
|
gptkbp:approvalYear
|
2021
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L04AA54
|
|
gptkbp:brand
|
gptkb:Empaveli
gptkb:Aspaveli
|
|
gptkbp:CASNumber
|
2028263-64-7
|
|
gptkbp:chemicalFormula
|
C192H296N52O64
|
|
gptkbp:developer
|
gptkb:Apellis_Pharmaceuticals
|
|
gptkbp:indication
|
gptkb:paroxysmal_nocturnal_hemoglobinuria
geographic atrophy secondary to age-related macular degeneration
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
C3 complement inhibitor
|
|
gptkbp:pregnancyCategory
|
gptkb:unknown
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
diarrhea
abdominal pain
fatigue
injection site reaction
infections
|
|
gptkbp:target
|
gptkb:complement_component_3_(C3)
|
|
gptkbp:UNII
|
6QY1D9Y4F1
|
|
gptkbp:usedFor
|
gptkb:geographic_atrophy
gptkb:paroxysmal_nocturnal_hemoglobinuria
|
|
gptkbp:bfsParent
|
gptkb:Empaveli
gptkb:Syfovre
gptkb:geographic_atrophy
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pegcetacoplan
|